×
About 10,192 results

ALLMedicine™ Myasthenia Gravis Center

Research & Reviews  4,865 results

Tuberculosis in Myasthenia Gravis patients on immunosuppressive therapy in a high-risk ...
https://doi.org/10.1016/j.jns.2021.117447
Journal of the Neurological Sciences; Steyn EC, Naidoo TM et. al.

Apr 20th, 2021 - Data regarding the risk of tuberculosis (TB) in myasthenia gravis (MG) patients receiving immunosuppressive therapy is limited, and the benefit of TB preventative therapy in these patients is uncertain. We audited observational data collected at a...

CYP3A5*3 polymorphism and age affect tacrolimus blood trough concentration in myastheni...
https://doi.org/10.1016/j.jneuroim.2021.577571
Journal of Neuroimmunology; Fan Z, Zheng D et. al.

Apr 18th, 2021 - The study aims to identify clinical factors affecting tacrolimus blood trough concentration (C0) in myasthenia gravis (MG) patients and to optimize the initial dose of tacrolimus in MG treatment. A total of 103 MG patients participated in this stu...

External treatment of traditional Chinese medicine for myasthenia gravis: A protocol fo...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8051982
Medicine Peng Y, Lu B et. al.

Apr 13th, 2021 - Myasthenia gravis (MG) is an archetypal autoimmune disorder. The conventional treatments for this disease are drugs, plasma exchange, surgical, and so on. However, this disease is difficult to cure. A mass of studies revealed that the external tre...

Rest or 30-Min Walk as Exercise Intervention (RESTOREX) in Myasthenia Gravis: A Randomi...
https://doi.org/10.1159/000513668
European Neurology; Misra UK, Kalita J et. al.

Apr 11th, 2021 - There is a lack of evidence about the usefulness of exercise or rest in myasthenia gravis (MG). This study is aimed to evaluate the efficacy and safety of exercise or rest in MG. In a single-center open-labeled randomized controlled trial, the pat...

Use of Remdesivir in Myasthenia Gravis and COVID-19.
https://doi.org/10.1002/phar.2524
Pharmacotherapy Peters BJ, Rabinstein AA et. al.

Apr 9th, 2021 - Myasthenia gravis and the associated pharmacologic management options could place patients at higher risk of contracting severe acute respiratory syndrome coronavirus 2 and exhibiting more severe manifestations of the novel coronavirus disease 201...

see more →

Guidelines  13 results

Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic synd...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7105910
Journal of the Neurological Sciences; , Jacob S et. al.

Apr 4th, 2020 - Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic.|2020| ,Jacob S,Muppidi S,Guidon A,Guptill J,|complications,drug therapy,epidemiology,therapeutic use,therapeutic use,t...

The Association of British Neurologists' myasthenia gravis guidelines.
https://doi.org/10.1111/nyas.13503
Annals of the New York Academy of Sciences; Sussman J, Farrugia ME et. al.

Nov 9th, 2017 - Myasthenia gravis (MG) is an autoimmune disease of the neuromuscular junction for which many therapies were developed before the era of evidence-based medicine. Despite the basic principles of treatment being well known, patients continue to recei...

International consensus guidance for management of myasthenia gravis: Executive summary.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4977114
Neurology Sanders DB, Wolfe GI et. al.

Jun 30th, 2016 - To develop formal consensus-based guidance for the management of myasthenia gravis (MG). In October 2013, the Myasthenia Gravis Foundation of America appointed a Task Force to develop treatment guidance for MG, and a panel of 15 international expe...

Guidelines for treatment of autoimmune neuromuscular transmission disorders.
https://doi.org/10.1111/j.1468-1331.2010.03019.x
European Journal of Neurology; Skeie GO, Apostolski S et. al.

Apr 20th, 2010 - Important progress has been made in our understanding of the autoimmune neuromuscular transmission (NMT) disorders; myasthenia gravis (MG), Lambert-Eaton myasthenic syndrome (LEMS) and neuromyotonia (Isaacs' syndrome). To prepare consensus guideli...

EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological ...
https://doi.org/10.1111/j.1468-1331.2008.02246.x
European Journal of Neurology; Elovaara I, Apostolski S et. al.

Sep 17th, 2008 - Despite high-dose intravenous immunoglobulin (IVIG) is widely used in treatment of a number of immune-mediated neurological diseases, the consensus on its optimal use is insufficient. To define the evidence-based optimal use of IVIG in neurology, ...

see more →

Drugs  57 results see all →

Clinicaltrials.gov  5,055 results

Tuberculosis in Myasthenia Gravis patients on immunosuppressive therapy in a high-risk ...
https://doi.org/10.1016/j.jns.2021.117447
Journal of the Neurological Sciences; Steyn EC, Naidoo TM et. al.

Apr 20th, 2021 - Data regarding the risk of tuberculosis (TB) in myasthenia gravis (MG) patients receiving immunosuppressive therapy is limited, and the benefit of TB preventative therapy in these patients is uncertain. We audited observational data collected at a...

Soliris - eculizumab injection, solution, concentrate-Alexion Pharmaceuticals Inc.
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ebcd67fa-b4d1-4a22-b33d-ee8bf6b9c722

Apr 19th, 2021 - Soliris is a complement inhibitor indicated for: The treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis (1.1). The treatment of patients with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-med...

CYP3A5*3 polymorphism and age affect tacrolimus blood trough concentration in myastheni...
https://doi.org/10.1016/j.jneuroim.2021.577571
Journal of Neuroimmunology; Fan Z, Zheng D et. al.

Apr 18th, 2021 - The study aims to identify clinical factors affecting tacrolimus blood trough concentration (C0) in myasthenia gravis (MG) patients and to optimize the initial dose of tacrolimus in MG treatment. A total of 103 MG patients participated in this stu...

External treatment of traditional Chinese medicine for myasthenia gravis: A protocol fo...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8051982
Medicine Peng Y, Lu B et. al.

Apr 13th, 2021 - Myasthenia gravis (MG) is an archetypal autoimmune disorder. The conventional treatments for this disease are drugs, plasma exchange, surgical, and so on. However, this disease is difficult to cure. A mass of studies revealed that the external tre...

Rest or 30-Min Walk as Exercise Intervention (RESTOREX) in Myasthenia Gravis: A Randomi...
https://doi.org/10.1159/000513668
European Neurology; Misra UK, Kalita J et. al.

Apr 11th, 2021 - There is a lack of evidence about the usefulness of exercise or rest in myasthenia gravis (MG). This study is aimed to evaluate the efficacy and safety of exercise or rest in MG. In a single-center open-labeled randomized controlled trial, the pat...

see more →

News  181 results

New Steroid Dosing Regimen for Myasthenia Gravis
https://www.medscape.com/viewarticle/945898

Feb 15th, 2021 - The findings of a new randomized trial support the rapid tapering of prednisone in patients with generalized myasthenia gravis requiring combined corticosteroid and azathioprine therapy. The trial showed that the conventional slow tapering regimen...

Ocular Side Effects Possible With Checkpoint Inhibitors
https://www.medscape.com/viewarticle/941652

Nov 26th, 2020 - NEW YORK (Reuters Health) - People who use immune-checkpoint inhibitors have an increased risk of noninfectious uveitis and myasthenia gravis, according to a database study. Several case series have reported ocular side effects of checkpoint inhib...

COVID-19 Linked to Development of Myasthenia Gravis
https://www.staging.medscape.com/viewarticle/935985

Aug 18th, 2020 - Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. Myasthenia gravis should be added to the growing list of potential neurological sequelae associated with COVID-19, new research suggests. Clinicia...

COVID-19 Linked to Development of Myasthenia Gravis
https://www.medscape.com/viewarticle/935985

Aug 18th, 2020 - Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. Myasthenia gravis should be added to the growing list of potential neurological sequelae associated with COVID-19, new research suggests. Clinicia...

Rituximab Promising in New-Onset Myasthenia Gravis
https://www.staging.medscape.com/viewarticle/930271

May 10th, 2020 - Patients with myasthenia gravis (MG) who are treated early with the monoclonal antibody rituximab (multiple brands) achieve remission sooner than those treated later in the disease process, new research suggests. Investigators compared patients wi...

see more →

Patient Education  21 results see all →